Published in N Engl J Med on August 29, 1996
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A (1998) 2.86
Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ (2003) 2.40
Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev (2012) 2.22
Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab (2005) 1.67
Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol (2005) 1.65
Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril (2007) 1.55
Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab (2002) 1.47
Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 1.17
Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol (2009) 1.14
Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ (1998) 1.11
The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci (2011) 1.09
Ovarian steroids: the good, the bad, and the signals that raise them. Cell Cycle (2006) 1.05
Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev (2012) 1.05
Insulin resistance. BMJ (1996) 1.00
Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes (2013) 0.97
Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab (2008) 0.96
Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diab Vasc Dis Res (2009) 0.96
Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril (2006) 0.95
Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med (2012) 0.94
Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod (2011) 0.94
Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab Syndr Relat Disord (2010) 0.91
State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). Int J Pediatr Endocrinol (2011) 0.90
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab (2008) 0.89
Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. Clin Endocrinol (Oxf) (2013) 0.89
Childhood obesity and its impact on the development of adolescent PCOS. Semin Reprod Med (2014) 0.89
Metformin: direct inhibition of rat ovarian theca-interstitial cell proliferation. Fertil Steril (2012) 0.87
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab (2014) 0.87
Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. Reprod Biol Endocrinol (2014) 0.87
Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod (2008) 0.85
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. Fertil Steril (2010) 0.84
Insulin and the polycystic ovary syndrome. N Engl J Med (1996) 0.84
Effect of Metformin on Hormonal and Biochemical Profile in PCOS Before and After Therapy. Indian J Clin Biochem (2010) 0.84
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev (2016) 0.83
Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2010) 0.82
Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab (2010) 0.82
Maternal undernutrition induces premature reproductive senescence in adult female rat offspring. Fertil Steril (2014) 0.82
Genetics in endocrinology: genetic forms of severe insulin resistance: what endocrinologists should know. Eur J Endocrinol (2013) 0.80
Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust. J Clin Endocrinol Metab (2010) 0.79
Prevalence of psychiatric disorders in patients with a diagnosis of polycystic ovary syndrome in kashmir. Indian J Psychol Med (2015) 0.79
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia (2017) 0.78
Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity. Obstet Gynecol Int (2012) 0.78
Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells. Steroids (2012) 0.78
Sugary food and beverage consumption and epithelial ovarian cancer risk: a population-based case-control study. BMC Cancer (2013) 0.78
Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab (2010) 0.78
Serum leptin and ghrelin levels in women with polycystic ovary syndrome: correlation with anthropometric, metabolic, and endocrine parameters. Int J Fertil Steril (2012) 0.77
The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome. Clin Biochem Rev (2007) 0.77
Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review. J Assist Reprod Genet (2013) 0.77
The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord (2014) 0.77
Genetic Rodent Models of Obesity-Associated Ovarian Dysfunction and Subfertility: Insights into Polycystic Ovary Syndrome. Front Endocrinol (Lausanne) (2016) 0.76
Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects. Reprod Biol Endocrinol (2014) 0.76
Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets (2015) 0.76
Sex hormone binding globulin measurement before conception as a predictor of gestational diabetes in women with polycystic ovarian syndrome. J Res Med Sci (2013) 0.75
Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study. J Biomed Res (2016) 0.75
The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment. J Assist Reprod Genet (2000) 0.75
Metformin therapy decreases hyperandrogenism and ovarian volume in women with polycystic ovary syndrome. Iran J Med Sci (2011) 0.75
Developmental Programming: Insulin Sensitizer Prevents the GnRH-Stimulated LH Hypersecretion in a Sheep Model of PCOS. Endocrinology (2016) 0.75
A cross-sectional study to assess any possible linkage of C/T polymorphism in CYP17A1 gene with insulin resistance in non-obese women with polycystic ovarian syndrome. Indian J Med Res (2016) 0.75
Can Sex-hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Int J Prev Med (2013) 0.75
[Insulin resistance in polycystic ovary syndrome]. Wien Klin Wochenschr (2003) 0.75
Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens. Physiology (Bethesda) (2017) 0.75
Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab (1998) 2.10
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med (1998) 2.04
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med (1999) 1.67
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab (1997) 1.21
Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women. J Clin Endocrinol Metab (1994) 0.90
Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab (1994) 0.87
Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab (2000) 0.79
The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab (1993) 0.77
Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci (1996) 0.77
Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab (1995) 0.75
Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab (1993) 0.75